OCRELIZUMAB AND HYALURONIDASE

499 reported adverse events

Drug classes: CD20-directed Cytolytic Antibody [EPC] Endoglycosidase [EPC]

These side effects are most commonly reported by patients taking OCRELIZUMAB AND HYALURONIDASE:

# Side effect Count
0 INJECTION SITE PAIN 66
1 INJECTION SITE ERYTHEMA 53
2 FATIGUE 48
3 PAIN 40
4 NO ADVERSE EVENT 29
5 OFF LABEL USE 29
6 HEADACHE 25
7 MULTIPLE SCLEROSIS RELAPSE 25
8 RASH 24
9 CONTUSION 23
See all common reactions for OCRELIZUMAB AND HYALURONIDASE

OCRELIZUMAB AND HYALURONIDASE is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 DESQUAMATIVE INFLAMMATORY VAGINITIS 1 0.0455
1 EPINEPHRINE DECREASED 1 0.0435
2 ADMINISTRATION SITE PRURITUS 1 0.0078
3 ADMINISTRATION SITE IRRITATION 1 0.0071
4 PARAGANGLION NEOPLASM 1 0.0068
5 GRANULOCYTOSIS 1 0.0051
6 VESTIBULAR MIGRAINE 1 0.0041
7 PATERNAL EXPOSURE BEFORE PREGNANCY 1 0.0033
8 INJECTION RELATED REACTION 5 0.0030
9 VITAMIN B1 DEFICIENCY 1 0.0023
See all enriched reactions for OCRELIZUMAB AND HYALURONIDASE